Children's Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Curr Opin Pediatr. 2020 Oct;32(5):668-673. doi: 10.1097/MOP.0000000000000938.
Chronic constipation is a common problem that substantially impacts the quality of life of patients and families, healthcare professionals, and resources. The purpose of this review is to discuss the medications that are available for management of chronic constipation, including medications that have been approved by the FDA for adults, other been studied in pediatrics now, and might become available within the upcoming years.
Recent developments in the evaluation of childhood constipation are providing a better understanding into defecation disorders in children and not only new therapies are becoming available, including medications, but also other therapies, such as biofeedback for treatment of functional defecation disorders, electrical stimulation, and surgeries. The aim of this article is to provide an update on the medications that are available for management of chronic constipation, especially with the development and study of newer medications, such as Linaclotide and Lubiprostone with promising results in both adult and pediatric patients.
This review will help us identify and have a better understanding regarding what medications are available for use and the indications, so that we can better manage patients with chronic constipation. VIDEO ABSTRACT.
慢性便秘是一种常见问题,严重影响患者及其家庭、医疗保健专业人员和资源的生活质量。本文的目的是讨论可用于治疗慢性便秘的药物,包括已获得美国食品药品监督管理局(FDA)批准用于成人的药物、目前正在儿科研究的其他药物以及未来可能上市的药物。
儿童便秘的评估方面的最新进展使我们对儿童排便障碍有了更好的理解,不仅有新的治疗方法,包括药物,还有其他治疗方法,如用于治疗功能性排便障碍的生物反馈、电刺激和手术。本文的目的是提供可用于治疗慢性便秘的药物的最新信息,特别是随着利那洛肽和鲁比前列酮等新药的开发和研究,这些药物在成人和儿科患者中均显示出良好的疗效。
本文将帮助我们了解和更好地理解可用的药物以及适应证,从而更好地管理慢性便秘患者。